Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 1.00 |
| ▸ | TDP2 | O95551 | 11/20 | 0.77 |
| ▸ | RAF1 | P04049 | 2/20 | 0.77 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.77 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | THRB | P10828 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | GALK1 | P51570 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181779 | 0.87 | TDP2 (1.00) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL2183740 | 0.87 | TDP2 (1.00) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL2180580 | 0.84 | TDP2 (1.00) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL2179691 | 0.84 | KDM4C (1.00) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL13272626 | 0.84 | TDP2 (0.74) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL3472472 | 0.84 | TDP2 (1.00) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL2186422 | 0.82 | KDM4C (1.00) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL2183454 | 0.82 | TDP2 (0.76) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL15032641 | 0.82 | TDP2 (0.76) | KDM4CTDP2RAF1MAP2K1SIRT1 | |
| SCHEMBL15032643 | 0.80 | TDP2 (0.84) | KDM4CTDP2RAF1MAP2K1SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | claimed |
| US-11129835-B2 | Methods and compositions for the inhibition of PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200093832-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10413548-B2 | Methods and compositions for the inhibition of Pin1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-07 | — | — | US | disclosed |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-07 | — | — | US | disclosed |
| US-20170304310-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-20170304310-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-9730941-B2 | Methods and compositions for the inhibition of Pin1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730941-B2 | Methods and compositions for the inhibition of Pin1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150133442-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| US-20150133442-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | PIN1, AS3MT, PML | KDM4C 3918/4885TDP2 1535/4885RAF1 971/4885 |
| US-20200093832-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | PIN1, FKBP1A, FKBP2 | KDM4C 2849/4885TDP2 2586/4885RAF1 2122/4885 |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | PIN1, AS3MT, PML | KDM4C 3918/4885TDP2 1535/4885RAF1 971/4885 |
| US-20150133442-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | PIN1, FKBP1A, FKBP2 | KDM4C 2849/4885TDP2 2586/4885RAF1 2122/4885 |
| US-20170304310-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | PIN1, FKBP1A, FKBP2 | KDM4C 2849/4885TDP2 2586/4885RAF1 2122/4885 |
| US-11129835-B2 | Methods and compositions for the inhibition of PIN1 | PIN1, FKBP1A, FKBP2 | KDM4C 2849/4885TDP2 2586/4885RAF1 2122/4885 |
| US-10413548-B2 | Methods and compositions for the inhibition of Pin1 | PIN1, FKBP1A, FKBP2 | KDM4C 2849/4885TDP2 2586/4885RAF1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.